B2BROKER
20.10.2020 11:02:05 CEST | Business Wire | Press release
B2Broker , a leading liquidity and technology provider of solutions to the forex and crypto industry, is pleased to announce it has launched its new website and new corporate branding. This is the company’s first major website and corporate identity update and is aligned with its expansion plans to position itself as the leading global provider in its genre, having secured over 200 institutional customers to date.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201020005105/en/
Rationale
While the last few months have presented a challenging situation regarding the Covid-19 global pandemic, B2Broker noted the increases in online trading which impacted on demand for Forex and crypto-related services from brokerages. The situation served as an important trigger to move forward with the new website and branding project to provide current and potential clients access to encyclopedic information and a new experience that is an industry first.
The rationale is summed up by B2Broker Chief Operating Officer, Evgeniya Mykulyak. “We created the previous version of our website two years ago and a lot has since changed…over the course of a year, 15 team members set out to build the best website in the industry, which would not only reflect the full essence of our products, but also provide general information about the industry. Our new logo meanwhile, reflects new values and meanings that are really close to the heart of our company, our team and our products.”
New Branding
The new brand strategy involves the use of 9 circles representing the 9 product groups with the circles depicting the products being perfectly formed like circles, allowing clients to build their business like a jigsaw using the company’s products. The square surrounding the image reflects the security and stability of the company’s products, whilst the colour green represents profitability and margin and the shades - market growth and vitality.
Rollout
The new B2Broker website which has been released in 8 languages officially launched on 14th October, 2020 with clients now being referred to the new domain www.b2broker.com
Arthur Azizov, CEO B2Broker, added, “B2Broker is now in its 6th year of successful operations and our new website and branding is an important milestone in the company’s growth and development. Our newly introduced branding reflects our prime position in the industry, the breadth of technology and liquidity services we offer and the global nature of our operations. This is an exciting company with even bigger plans for the market, and now we have a state-of-the-art website and more distinctive brand that fully expresses our purpose.
About B2Broker
B2Broker’s range of products and services include: Cryptocurrency Liquidity , Forex Liquidity , CFD Liquidity , Forex Broker Turnkey , Crypto Broker Turnkey , Crypto Payment Gateway , B2Core (Trader’s Room and Back Office Software), Investment Platform , MT4 / MT5 White Label solutions , Cryptocurrency Exchange Development and www.b2bx.exchange , all of which contribute to the company’s growing presence across the globe.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201020005105/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom